Effects of Empagliflozin on Fluid Overload, Weight, and Blood Pressure in CKD
Kaitlin J. Mayne, William G. Herrington(Oxford Health NHS Foundation Trust), Jennifer B. Green, John Nolan(University of Oxford), Natalie Staplin(University of Oxford), David Z.I. Cherney(University Health Network), Daniele Trinca(Leeds Teaching Hospitals NHS Trust), Colin Baigent(University of Oxford), Jonathan Emberson(University of Oxford), Christoph Wanner(Universitätsklinikum Würzburg), Vladimir Cejka(Universitätsklinikum Würzburg), David Preiss(Medical Research Council), Johannes Stegbauer(Düsseldorf University Hospital), Patrick B. Mark(Queen Elizabeth University Hospital), Katherine R. Tuttle(Providence Regional Medical Center Everett), Ryonfa Lee(University of Oxford), Dominik Steubl(Boehringer Ingelheim (Germany)), Jennifer S. Lees(NHS Greater Glasgow and Clyde), David Keane(Ollscoil na Gaillimhe – University of Galway), Akiko Omata(University of Oxford), Martin Landray(Gentofte Hospital), Roberto Pontremoli(Ospedale Policlinico San Martino), Susanne Brenner, Sibylle J. Hauske(Heidelberg University), Richard Haynes, Simon Davies(Keele University), Martina Brückmann(Boehringer Ingelheim (Germany)), Lai Seong Hooi(Sultanah Aminah Hospital), Rejive Dayanandan(University of Oxford), Parminder K. Judge(University of Oxford)
Cited by 46
Related Papers
Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis
|The Lancet|2015|3.7k
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
|New England Journal of Medicine|2016|3.6k
Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19
|JAMA|2020|2.4k
Interpretation of the evidence for the efficacy and safety of statin therapy
|The Lancet|2016|1.8k